“…In mice with gastric PM xenografts, IP administration of DFP-10825 showed promising results. 88 Without causing severe side effects (because of very limited distribution to blood circulation), the drug inhibited tumor growth and prolonged survival time. Notably, DFP-10825 showed greater growth-inhibitory effects than conventional S1 treatment (5-FU prodrug tegafur, gimeracil, and oteracil) on tumors disseminated in peritoneum.…”